Prophylactic Effects of Esketamine in Surgical Patients
Status:
Not yet recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
Evidences have showing that esketamine has anti-inflammatory and therapeutic effects on
depression and cardiac surgery. The investigators' preliminary results suggest that combined
prophylactic and therapeutic use of esketamine could decrease the plasma levels of
pro-inflammatory cytokines after LPS-induced endotoxemia. The investigators also found that
combined prophylactic and therapeutic use of esketamine could attenuate systemic inflammation
and inflammatory multi-organ injury in mice after CLP-induced lethal sepsis.
Surgical trauma could elicit a marked inflammatory response with increased expression of
pro-inflammatory cytokines, as well as postoperative immunosuppression. However, it remains
unclear whether combined prophylactic and therapeutic use of esketamine could improve
postoperative immunosuppression and alleviates systemic inflammatory response.
This project aims to study whether combined prophylactic and therapeutic use of esketamine
could improve the decreased number of lymphocyte subsets and increased plasma
pro-inflammatory cytokines.